scholarly journals Lower Daily Carbohydrate Intake is associated with Improved Glycemic Control in Adults with Type 1 Diabetes using a Hybrid Closed-Loop System

2020 ◽  
Author(s):  
Vera Lehmann ◽  
Thomas Zueger ◽  
Anna Zeder ◽  
Sam Scott ◽  
Lia Bally ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Closed Loop ◽  
Glucose Monitoring ◽  
Closed Loop System ◽  
Female Age ◽  
Time In Range ◽  
Design And Methods

<i>Objective</i> <p>To assess the association between daily carbohydrate (CHO) intake and glycemic control in adult hybrid closed-loop (HCL) users with type 1 diabetes mellitus (T1D).</p> <p><i>Research Design and Methods</i></p> <p>Mean individual daily CHO intake (MIDC) and deviation from MIDC (rMIDC; ≤80% low; 81-120% medium, >120% high CHO consumption) were compared with parameters of glycemic control assessed by continuous glucose monitoring (CGM). </p> <p><i>Results</i></p> <p>Records from 36 patients (26 male, 10 female; age 36.9±13.5y; HbA<sub>1c</sub> 7.1±0.9% [54±10mmol/mol]) provided 810 days of data (22.5±6.7 days per patient). Time in range (70-180mg/dL) for low, medium, and high CHO consumption was 77.4±15.4%, 75.2±16.7% and 70.4±17.8%, respectively (<i>p</i><0.001). Time above range (>180mg/dL) was 20.1±14.7%, 22.0±16.9% and 27.2±18.4%, respectively (<i>p</i><0.001). There was no between-group difference for time in hypoglycemia (<70mg/dL; <i>p</i>=0.50).</p> <p><i>Conclusions</i></p> Daily CHO intake was inversely associated with glycemic control in adults with T1D using a HCL system. Lower CHO intake may be a strategy to optimize glucose control in HCL users.

scholarly journals Lower Daily Carbohydrate Intake is associated with Improved Glycemic Control in Adults with Type 1 Diabetes using a Hybrid Closed-Loop System

2020 ◽  
Author(s):  
Vera Lehmann ◽  
Thomas Zueger ◽  
Anna Zeder ◽  
Sam Scott ◽  
Lia Bally ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Closed Loop ◽  
Glucose Monitoring ◽  
Closed Loop System ◽  
Female Age ◽  
Time In Range ◽  
Design And Methods

<i>Objective</i> <p>To assess the association between daily carbohydrate (CHO) intake and glycemic control in adult hybrid closed-loop (HCL) users with type 1 diabetes mellitus (T1D).</p> <p><i>Research Design and Methods</i></p> <p>Mean individual daily CHO intake (MIDC) and deviation from MIDC (rMIDC; ≤80% low; 81-120% medium, >120% high CHO consumption) were compared with parameters of glycemic control assessed by continuous glucose monitoring (CGM). </p> <p><i>Results</i></p> <p>Records from 36 patients (26 male, 10 female; age 36.9±13.5y; HbA<sub>1c</sub> 7.1±0.9% [54±10mmol/mol]) provided 810 days of data (22.5±6.7 days per patient). Time in range (70-180mg/dL) for low, medium, and high CHO consumption was 77.4±15.4%, 75.2±16.7% and 70.4±17.8%, respectively (<i>p</i><0.001). Time above range (>180mg/dL) was 20.1±14.7%, 22.0±16.9% and 27.2±18.4%, respectively (<i>p</i><0.001). There was no between-group difference for time in hypoglycemia (<70mg/dL; <i>p</i>=0.50).</p> <p><i>Conclusions</i></p> Daily CHO intake was inversely associated with glycemic control in adults with T1D using a HCL system. Lower CHO intake may be a strategy to optimize glucose control in HCL users.

1066-P: Improvement in Time-in-Range (TIR) with Real-Life Use of Hybrid Closed-Loop System in Patients with Type 1 Diabetes (T1D)

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1066-P
Author(s):  
HALIS K. AKTURK ◽  
DOMINIQUE A. GIORDANO ◽  
HAL JOSEPH ◽  
SATISH K. GARG ◽  
JANET K. SNELL-BERGEON
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Real Life ◽  
Loop System ◽  
Closed Loop System ◽  
Time In Range

102-LB: Six-Month Glycemic Control with a Hybrid Closed-Loop System in Type 1 Diabetes Patients during COVID-19 Pandemic in Argentina

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 102-LB
Author(s):  
ADRIAN E. PROIETTI ◽  
MARCIAL A. ANGÓS ◽  
ALEJANDRO DAIN ◽  
MARIELA I. ECHENIQUE ◽  
MARÍA L. KABAKIAN ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Closed Loop ◽  
Loop System ◽  
Closed Loop System ◽  
Diabetes Patients

Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up

2021 ◽  
Author(s):  
Coralie Amadou ◽  
Sylvia Franc ◽  
Pierre-Yves Benhamou ◽  
Sandrine Lablanche ◽  
Erik Huneker ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Adverse Events ◽  
Closed Loop ◽  
Artificial Pancreas ◽  
Real Life ◽  
Serious Adverse Events ◽  
Life Conditions ◽  
Time In Range

<b>OBJECTIVE </b> <p>To analyze safety and efficacy of the DBLG1 hybrid closed-loop artificial pancreas system in patients with Type 1 Diabetes in real life conditions. </p> <p> </p> <p><b>METHODS</b></p> <p>Following a one-week run-in period with usual pump, 25 patients were provided with the commercial DBLG1 system. We present the results of Time-in-Range and HbA1c over a 6-month period.</p> <p><b> </b></p> <p><b>RESULTS</b></p> <p>The mean (SD;range) age of patients was 43 years (13.8; 25-72). At baseline, mean HbA1c and TIR 70-180mg/dL were respectively 7.9% (0.93; 5.6- 8.5) [63mmol/mol (10; 38-69)] and 53% (16.4;21-85). One patient stopped using the system after 2 months. At 6-month, mean HbA1c decreased to 7.1% [54mmol/mol] (p<0.001) and TIR 70-180mg/dL increased to 69.7% (p<0.0001). TIR<70mg/dL decreased from 2.4 to 1.3% (p=0.03). TIR<54mg/dL decreased from 0.32 to 0.24% (p=0.42). No serious adverse event was reported during the study. </p> <p> </p> <p><b>CONCLUSION</b></p> <p>The DBLG1 System confirms its ability to significantly improve glycemic control in real life conditions, without serious adverse events. </p>

Neue Entwicklungen bei Diabetes mellitus Typ 1

2021 ◽  
Vol 146 (11) ◽  
pp. 710-713
Author(s):  
Linus Haberbosch ◽  
Joachim Spranger
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Aspart ◽  
Closed Loop ◽  
Glucose Monitoring ◽  
Loop System ◽  
Diabetes Mellitus Typ 1 ◽  
Closed Loop System ◽  
Neue Entwicklungen ◽  
Time In Range ◽  
Fast Acting

Was ist neu? Monitoring Mit der zunehmenden Prävalenz von Continuous-Glucose-Monitoring (CGM) -Systemen gewinnt die Time in Range (TIR) als Parameter zur Optimierung der Blutzuckereinstellung bei Patienten mit Diabetes mellitus Typ 1 an Bedeutung. Zuletzt erfolgte der Nachweis einer verbesserten Prävention von kardiovaskulären Ereignissen und Schwangerschaftskomplikationen bei Patienten mit optimierter TIR. Zusätzlich zur TIR wird empfohlen, die Time below Range (TBR) zu erheben, um Hypoglykämien als klinisch relevante Ereignisse ebenfalls zu erfassen. Hypoglykämien Hypoglykämien bleiben eine klinisch relevante Komplikation der Therapie des Diabetes mellitus Typ 1. Mit der Zulassung von nasalem Glukagon besteht nun gegenüber der klassischen Injektion eine Option als einfach anzuwendende Notfalltherapie. Mit der Entwicklung des im flüssigen Zustand stabilen Glukagon-Analogons Dasiglukagon steht potenziell in naher Zukunft darüber hinaus ein klassischer Notfall-Pen mit Fertiglösung zur Verfügung. Insulintherapie Das neue schnellwirksame Insulin aspart (fast-acting Insulin aspart, FIASP) bietet neue Chancen für die Blutzuckeroptimierung von Typ-1-Diabetespatienten. 2019 wurde darüber hinaus das erste Hybrid-Closed-Loop-System zur Behandlung des Diabetes mellitus Typ 1 in Deutschland zugelassen. Bei diesem System erfolgt eine automatische Anpassung der Basalrate anhand des per CGM gemessenen Blutzuckers. Aufgrund der weiterhin notwendigen Bolusgaben und der Komplexität der Technologie bleibt eine sorgfältige Auswahl und adäquate Schulung der mit einem solchen System therapierten Patienten essenziell. Bei adäquater Anwendung ermöglicht ein Hybrid-Closed-Loop-System eine verbesserte Einstellung insbesondere des nächtlichen Blutzuckers. Ergänzende Therapien Seit 2019 sind der SGLT-2-Inhibitor Dapagliflozin und der kombinierte SGLT-1/2-Inhibitor Sotagliflozin für die Therapie von unzureichend eingestellten Typ-1-Diabetikern mit einem BMI über 27 kg/m² und ohne Risikokonstellation für diabetische Ketoazidosen zugelassen. Die relevanteste Nebenwirkung ist die atypische normoglykäme Ketoazidose, weshalb eine initiale Risikoeinschätzung sowie eine angemessene Schulung des Patienten zur Durchführung und Interpretation von Ketonkörper- und pH-Messungen unter der Therapie von zentraler Bedeutung sind.  

scholarly journals Lower Daily Carbohydrate Intake Is Associated With Improved Glycemic Control in Adults With Type 1 Diabetes Using a Hybrid Closed-Loop System

Diabetes Care ◽  
2020 ◽  
Vol 43 (12) ◽  
pp. 3102-3105
Author(s):  
Vera Lehmann ◽  
Thomas Zueger ◽  
Anna Zeder ◽  
Sam Scott ◽  
Lia Bally ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glycemic Control ◽  
Closed Loop ◽  
Loop System ◽  
Carbohydrate Intake ◽  
Closed Loop System

Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes.

2021 ◽  
Author(s):  
Pilar Isabel Beato-Víbora ◽  
Fabiola Gamero-Gallego ◽  
Ana Ambrojo-López ◽  
Estela Gil-Poch ◽  
Irene Martin-Romo ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Closed Loop ◽  
Loop System ◽  
Closed Loop System ◽  
Rapid Improvement ◽  
Adolescents And Adults ◽  
Time In Range

scholarly journals Short-term use of continuous glucose monitoring system adds to glycemic control in young type 1 diabetes mellitus patients in the long run: A clinical trial

2011 ◽  
Vol 68 (8) ◽  
pp. 650-654 ◽  
Author(s):  
Gordana Bukara-Radujkovic ◽  
Dragan Zdravkovic ◽  
Sinisa Lakic
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Blood Glucose ◽  
Glycemic Control ◽  
Type 1 Diabetes Mellitus ◽  
Glucose Monitoring ◽  
Control Group ◽  
Short Term ◽  
Experimental Group

Background/Aim. Balancing strict glycemic control with setting realistic goals for each individual child and family can optimize growth, ensure normal pubertal development and emotional maturation, and control long term complications in children with type 1 diabetes (T1DM). The aim of this study was to evaluate the efficacy of short-term continuous glucose monitoring system (CGMS) application in improvement of glycemic control in pediatric type 1 diabetes mellitus (T1DM) patients. Methods. A total of 80 pediatric T1DM patients were randomly assigned into the experimental and the control group. The experimental group wore CGMS sensor for 72 hours at the beginning of the study. Self-monitored blood glucose (SMBG) levels and hemoglobin A1c (HbA1c) levels were obtained for both groups at baseline, and at 3 and 6 months. Results. There was a significant improvement in HbA1c (p < 0.001), in both the experimental and the control group, without a significant difference between the groups. Nevertheless, after 6 months the improvement of mean glycemia was noticed only in the experimental group. This finding was accompanied with a decrease in the number of hyperglycemic events and no increase in the number of hypoglycemic events in the experimental group. Conclusions. The results suggest that the CGMS can be considered as a valuable tool in treating pediatric T1DM patients, however further research is needed to more accurately estimate to what extent, if any, it outperforms intensive self-monitoring of blood glucose.

Sign in / Sign up

Export Citation Format

Share Document